Agios Pharmaceuticals Reports Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Azacitidin; Reports ORR of 78%, CR Rate of 44% and CR/CRi/CRp Rate of 65% in the Ivosidenib Arm; Molecular Clearance Observed in 7 Out of 21 Patients